SI
SNDX icon

Sofinnova Investments’s Syndax Pharmaceuticals SNDX Stock Holding History

Sofinnova Investments’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-600,000
Closed -$8.71M – 76
2023
Q3 		$8.71M Buy
+600,000
New +$11.3M 0.55% 38
2019
Q4 		– Sell
-100,000
Closed -$746K – 68
2019
Q3 		$746K Buy
+100,000
New +$911K 0.07% 70

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Sofinnova Investments's SNDX Position: Q3 2025 in Review

Sofinnova Investments sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 1,524,440 shares — an estimated $14.3M sold.

Sofinnova Investments first reported a position in SNDX in Q1 2018 and held it in 26 quarters. The position peaked at $44.2M in Q2 2024. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

  • Sofinnova Investments reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Sofinnova Investments sold 1,524,440 Syndax Pharmaceuticals shares in Q3 2025, an estimated $14.3M.
  • Sofinnova Investments first reported a position in Syndax Pharmaceuticals in Q1 2018 and held it in 26 quarters.
  • Sofinnova Investments's Syndax Pharmaceuticals position peaked at $44.2M in Q2 2024.
  • 227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Sofinnova Investments's 13F filing for Q3 2025, filed 14 Nov 2025.